• 1. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 2. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 3. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 4. Dissolution of cork biopolymers in biocompatible ionic liquids
  Helga Garcia,Rui Ferreira,Marija Petkovic,Jamie L. Ferguson,Maria C. Leit?o,H. Q. Nimal Gunaratne,Luís Paulo N. Rebelo Green Chem., 2010,12, 367-369
• 5. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzenesulfonamides

Recent Advances in the Study of 3-Methyl-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine (CAS: 1186501-89-2)

3-Methyl-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine (CAS: 1186501-89-2) is a heterocyclic compound that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential as a versatile scaffold for drug discovery. Recent studies have explored its pharmacological properties, synthetic pathways, and applications in targeting various diseases, particularly in oncology and neurology. This research brief aims to summarize the latest findings related to this compound, highlighting its molecular mechanisms, therapeutic potential, and future research directions.

One of the key areas of interest is the role of 3-Methyl-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine as an inhibitor of specific protein kinases. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy in selectively targeting aberrant kinase activity in cancer cells, leading to apoptosis and reduced tumor growth in preclinical models. The compound's unique sulfonyl and pyrrolopyridine moieties contribute to its high binding affinity and selectivity, making it a promising candidate for further development as an anticancer agent.

In addition to its anticancer properties, recent research has also investigated the compound's potential in neurodegenerative diseases. A study in ACS Chemical Neuroscience (2024) reported that derivatives of 3-Methyl-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine exhibited neuroprotective effects in models of Alzheimer's disease by modulating tau protein aggregation and reducing oxidative stress. These findings suggest that the compound could serve as a lead structure for developing novel therapeutics for neurodegenerative disorders.

The synthetic accessibility of 3-Methyl-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine has also been a focus of recent research. A 2024 paper in Organic Letters detailed an optimized synthetic route that improves yield and scalability, addressing previous challenges in large-scale production. This advancement is critical for facilitating further pharmacological studies and potential clinical translation.

Despite these promising developments, challenges remain in optimizing the pharmacokinetic and safety profiles of 3-Methyl-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine and its derivatives. Future research should focus on structure-activity relationship (SAR) studies to enhance efficacy and reduce off-target effects. Collaborative efforts between chemists, biologists, and clinicians will be essential to unlock the full therapeutic potential of this compound.

In conclusion, 3-Methyl-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine (CAS: 1186501-89-2) represents a compelling area of research in chemical biology and drug discovery. Its diverse pharmacological activities and synthetic versatility position it as a valuable tool for addressing unmet medical needs in oncology and neurology. Continued exploration of its mechanisms and applications will likely yield significant contributions to the field in the coming years.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)